A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients
- Status
- UNKNOWN
- Phase
- N/A
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Status
- RECRUITING
- Phase
- PHASE1
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
AB122 Platform Study
- Status
- RECRUITING
- Phase
- PHASE1
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE2
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
- Status
- UNKNOWN
- Phase
- PHASE2